chartexchange

Pharming: 3 Key Takeaways for Long-Term Investors

The Motley Fool | Nov 4, 2026 5:00 PM EST

On its third-quarter 2026 earnings call, held on Oct. 27, 2026, Pharming (NASDAQ:PHAR) announced total revenue grew 21% to $117.6 million. Operating profit increased 89% to $29.9 million as the business expanded sales of its primary rare disease treatments. Strong cash generation gives the business funding to expand its clinical drug pipeline without needing extra financing. Three things management said stand out. RUCONEST, a treatment for hereditary angioedema (HAE, a rare genetic condition causing severe swelling), returned to revenue growth after earlier quarterly declines. Management maintained over 90% of active patients despite new oral competition, stabilizing demand among high-volume users. Continue reading

Read original article